Research

Piedmont Investment Advisors LLC Purchases New Stake in Gilead Sciences, Inc. (GILD)

Share
Curing Disease Is Bad For Business How Do Big Pharma Companies Continue Their Growth

In essence, the P/E ratio of Gilead Sciences Inc. specifies the dollar amount an investor can anticipate to invest in the company to receive one dollar of the company's earnings.

Some buy side analysts are also providing their Analysis on Gilead Sciences Inc., where 6 analysts have rated the stock as Strong buy, 11 analysts have given a Buy signal, 11 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell.

Growth Estimate for Gilead Sciences Inc. (NASDAQ:GILD) during the third quarter, according to its most recent disclosure with the SEC. For the next 5 years, the company is expected to grow by -6 percent. Comparatively, growth in the past five years was 66.85 percent (per annum).

Heading into the stock price potential, Gilead Sciences Inc. needs to grow just 16.95% to cross its median price target of $79. (NASDAQ:GILD) traded with the volume of 14.91 Million in the previous trading session. Studies indicate that the stock prices of firms with significant positive earnings surprises show above-average performance, while those with negative surprises have below-average performance. The higher estimate for the short term price target is at $118 while the lower estimate is at $74. The company had revenue of $7.30 billion for the quarter, compared to the consensus estimate of $7.16 billion. The High end of the Estimate is $7.1 Billion, while the Low end of the Estimate is $6.14 Billion. The business earned $7.30 billion during the quarter, compared to analysts' expectations of $7.16 billion. They now have a United States dollars 83 price target on the stock. 23 Analysts think that the Price Target for Gilead Sciences Inc.

02/08/2017 - Gilead Sciences, Inc. had its "outperform" rating reiterated by analysts at Credit Suisse.

"Jefferies Group Comments on Gilead Sciences, Inc.'s Q1 2017 Earnings (GILD)" was first published by BBNS and is owned by of BBNS. The Stock now has the market capitalization of $88.9 Billion, P/E (price to earnings ttm) of 6.8 and Weekly volatility of 2.09% and monthly volatility of 1.68% respectively. The Company has 52-week high of $103.1 and 52-week low of $65.38. The company has a 50-day moving average price of $71.95 and a 200 day moving average price of $75.44. The Company Touched its 52-Week High on April 26, 2016 and 52-Week Low on Feb 9, 2017. (NASDAQ:GILD) is 1.54. The Average Volume (3 months) is 10.3 Million.

Gilead Sciences Inc. has 1 year price target of $83.06. Gilead Sciences Inc. got Downgrade on 8-Feb-17 where investment firm Citigroup Downgrade the stock from Buy to Neutral. The company's Relative strength index is 36.23. The firm had put out a Buy rating.Previously, the coverage launch was announced by Mizuho on Nov 08, 2016, with a rating set to Buy.

In an overview of the current analyst recommendations, Buy count is 1 and Overweight is 0 while the number of analysts recommending Sell and Underweight are 0 and 0, respectively. The highest and lowest price target given by the brokerage firms to the equity are $142 and $70, respectively. The company now has an average rating of "Buy" and a consensus target price of $96.85.

Along with these its year to date performance is standing at -5.53%. TMD & Associates Inc. now owns 51,919 shares of the biopharmaceutical company's stock worth $4,108,000 after buying an additional 6,473 shares in the last quarter. Given the stock's recent action, it seemed like a good time to take a closer look at the company's recent data. It opened the session with a $68.6 price tag, later ranging from $67.33 to $68.67, the range at which the stock has traded at throughout the day. BlackRock Fund Advisors now owns 26,032,555 shares of the biopharmaceutical company's stock worth $2,059,696,000 after buying an additional 1,663,268 shares during the period. The company's stock has a Return on Assets (ROA) of 25.6 percent, a Return on Equity (ROE) of 82.9 percent and Return on Investment (ROI) of 72.4 percent. The biopharmaceutical company reported $2.70 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.61 by $0.09. The high end of the revenue guidance is $5.21 Billion and the low end is $4.88 Billion. The projected growth estimate for the next quarter is -30.8 percent.

Share